Zhe et al. reported that in the Non-Small Cell Lung Cancer (NSCLC) A549 cell model, baicalein inhibits the RhoA/ROCK signaling pathway in a dose-dependent manner, disrupts the cytoskeletal F-actin network, downregulates the expression of VM-related factors including VE-cadherin, EphA2, MMP2/9/14, PI3K, and LAMC2, and blocks the interaction between tumor cells and the ECM, thereby suppressing the formation of VM tubular structures (Zhang et al., 2020). Here, RHOA is linked to non-small cell lung carcinoma.